Drug Discovery

Pacira BioSciences to buy Flexion Therapeutics

Pacira BioSciences has signed a definitive agreement to acquire biopharmaceutical firm Flexion Therapeutics to strengthen its position in non-opioid pain management.

FDA accepts NDA for Acer and Relief’s urea cycle disorder therapy

The US Food and Drug Administration (FDA) has accepted the filing of a new drug application (NDA) for Acer Therapeutics and Relief Therapeutics’ ACER-001 (sodium phenylbutyrate) to treat people with urea cycle disorders (UCDs). 

AstraZeneca to acquire remaining stake in Caelum Biosciences

AstraZeneca’s subsidiary Alexion has announced plans to acquire all the remaining equity stake in Caelum Biosciences for up to $500m.

Appili, AiPharma partner to advance Avigan/Reeqonus global development

Appili Therapeutics has announced a strategic alliance with AiPharma to advance the global development of Avigan/Reeqonus (favipiravir).

UNION therapeutics, Innovent partner to develop and market orismilast in China

UNION therapeutics has signed a strategic collaboration and license agreement with Innovent Biologics for the development and commercialisation of orismilast in China.

Incyte and Syndax to jointly develop and commercialise axatilimab

Incyte has signed a collaboration and license agreement with Syndax Pharmaceuticals to develop and commercialise axatilimab for chronic graft-versus-host disease (cGVHD) and other fibrotic diseases.

AstraZeneca partners with VaxEquity on self-amplifying RNA therapeutics

AstraZeneca has entered a strategic, long-term research collaboration with biopharmaceutical firm VaxEquity to discover, develop and commercialise self-amplifying RNA (saRNA) therapeutics platform.

Tonix and Columbia University to develop tailored Covid-19 vaccines

Tonix Pharmaceuticals has expanded its research partnership with Columbia University in the US for the development of tailored Covid-19 vaccines and treatments with precision medicine.

AbCellera, Everest Medicines partner to discover new antibody therapies

Canadian biotechnology firm AbCellera has signed a collaboration and licence agreement with Everest Medicines to advance new antibody therapies.